Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
May-2015 Volume 9 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
May-2015 Volume 9 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells

  • Authors:
    • Yang Ye
    • Shuhan Miao
    • Yan Wang
    • Jianwei Zhou
    • Rongzhu Lu
  • View Affiliations / Copyright

    Affiliations: Department of Preventive Medicine, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China, Department of Molecular Cell Biology and Toxicology, Cancer Center, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
  • Pages: 2393-2397
    |
    Published online on: March 3, 2015
       https://doi.org/10.3892/ol.2015.3008
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) specifically kills cancer cells without destroying the majority of healthy cells. However, numerous types of cancer cell, including gastric cancer cells, tend to be resistant to TRAIL. The bioactive product 3,3'‑diindolylmethane (DIM), which is derived from cruciferous vegetables, is also currently recognized as a candidate anticancer agent. In the present study, a Cell Counting Kit 8 cell growth assay and an Annexin V‑fluorescein isothiocyanate apoptosis assay were performed to investigate the potentiating effect of DIM on TRAIL‑induced apoptosis in gastric cancer cells, and the possible mechanisms of this potentiation. The results obtained demonstrated that, compared with TRAIL or DIM treatment alone, co‑treatment with TRAIL (25 or 50 ng/ml) and DIM (10 µmol/l) induced cytotoxic and apoptotic effects in BGC‑823 and SGC‑7901 gastric cancer cells. Furthermore, western blot analysis revealed that the protein expression levels of death receptor 5 (DR5), CCAAT/enhancer binding protein homologous protein (CHOP) and glucose‑regulated protein 78 (GRP78) were upregulated in the co‑treated gastric cancer cells. To the best of our knowledge, the present study is the first to provide evidence that DIM sensitizes TRAIL‑induced inhibition of proliferation and apoptosis in gastric cancer cells, accompanied by the upregulated expression of DR5, CHOP and GRP78 proteins, which may be involved in endoplasmic reticulum stress mechanisms.

Introduction

Despite advancements in the prevention and treatment through multimodal approaches, including targeted therapies, gastric cancer is one of the most common types of malignant tumor and remains the second leading cause of carcinoma-associated mortality worldwide (1).

Few agents exist that are truly cancer cell specific with regards to the induction of cell death. For example, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an agent that is preferentially cytotoxic to cancer cells over healthy cells (2). However, the effectiveness of TRAIL is significantly impeded by drug resistance, resulting in poor survival outcomes of patients with cancer (3,4). Emerging evidence provides support for the potential anticancer effect of bioactive products derived from cruciferous vegetables, such as brussel sprouts, broccoli, cabbage and cauliflower (5). Among these compounds, 3,3′-diindolylmethane (DIM) is generated in the acidic environment of the stomach via dimerization of the indole-3-carbinol monomers present in these vegetables (6).

A number of cellular stress conditions, including nutrient deprivation, hypoxia and treatment with a variety of pharmacological agents which inhibit glycosylation or deplete endoplasmic reticulum (ER) calcium stores, may lead to the accumulation and aggregation of unfolded and/or misfolded proteins in the ER lumen, which is termed ER stress. Notably, ER-induced apoptotic cell death has been identified as an important apoptotic pathway (7). Various mechanisms have been hypothesized to exhibit an important role in ER stress-induced apoptosis; the C/enhancer binding protein homologous protein (CHOP), glucose-regulated protein 78 (GRP78) and caspase-3, −9 and −12 are all considered to be involved in the apoptotic signaling pathway which occurs in response to ER stress (8). In addition, it has been demonstrated that effective TRAIL-based combination therapy can be achieved by upregulating death receptor 5 (DR5) expression (9). Furthermore, CHOP has been reported to directly regulate DR5 expression in human carcinoma cells (10).

The aim of the present study was to explore whether DIM potentiates TRAIL-induced apoptosis of gastric cancer cells and investigate the possible mechanisms of this process.

Materials and methods

Cell culture

The human gastric cancer cell lines BGC-823 and SGC-7901 were purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum (Tianhang Biological Technology Co., Ltd., Hangzhou, China). All cells were maintained in a 5% CO2 atmosphere at a temperature of 37°C.

Cell growth assay

To determine cell growth, a colorimetric water-soluble tetrazolium salt assay (Cell Counting Kit 8; Dojindo Laboratories, Kumamoto, Japan) was performed. This allowed the number of viable cells to be evaluated following treatment with various agent combinations.

Apoptosis assay

The detection of apoptotic cells was performed using an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Beyotime Institute of Biotechnology, Nantong, China), according to the manufacturer's instructions. Cells were plated in 6-well plate (5×105 cells/well) and allowed to grow to 75–80% confluence. Following treatment with DIM (10 µmol/l), TRAIL (25 or 50 ng/ml) or DIM (10 µmol/l) + TRAIL (25 ng/ml) for 24 h, the cells were collected, resuspended in 500 µl binding buffer, and 5 µl Annexin V-FITC and 5 µl propidium iodide were added. Untreated cells were washed twice with phosphate-buffered saline (Beyotime Institute of Biotechnology), collected, resuspended in 500 µl binding buffer, and 5 µl Annexin V-FITC and 5 µl propidium iodide were added, which served as the control. The data was quantified and analyzed using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

Western blot analysis

Western blot analysis was conducted as previously described (11). Briefly, cells were lysed by incubating in lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS; pH 7.4; Beyotime Institute of Biotechnology) for 20 min at 4°C and the protein concentration was determined using the Beyotime assay system (Beyotime Institute of Biotechnology). Protein (60 µg) was run on 12.5% polyacrylamide gel and transferred to a nitrocellulose membrane (Hybond-ECL; Amersham Pharmacia Biotech, Buckinghamshire, UK). Next, the membrane was blocked with Tris-buffered saline containing 0.1% Tween 20 (TBST) and 5% nonfat milk for 2 h at room temperature and incubated overnight at 4°C with primary monoclonal antibodies against DR5 (cat. no. sc-166624), DR4 (cat. no. sc-8411), CCAAT/CHOP (cat. no. sc-7351), GRP78 (cat. no. sc-376768) and GAPDH (cat. no. sc-365062) purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The membrane was washed three times with TBST and incubated with horseradish peroxidase-conjugated goat anti-mouse secondary antibody (cat. no. A0216, Beyotime Institute of Biotechnology) for 1 h at room temperature. Immunoreactive bands were subsequently identified using LumiGLO® chemiluminescent substrate (Cell Signaling Technology, Inc.). The light emitted by destabilized LumiGLO® reagent was subsequently captured on X-ray film, (Cell Signaling Technology, Inc.), normalized to the corresponding GAPDH level and analyzed with ImageJ software (version 1.44; National Institutes of Health, Bethesda, MD, USA).

Statistical analysis

The SPSS software package (version 15.0; SPSS, Inc, Chicago, IL, USA) was used for data analysis, with data presented as the mean ± standard deviation (SD) and n indicating the number of independent experiments performed. After determining equal variance, comparisons among the means of multiple groups were performed using one-way analysis of variance and Fisher's least significant difference test. Additionally, two-tailed independent samples t-tests were used when appropriate. P<0.05 was considered to indicate a statistically significant difference.

Results

DIM sensitizes gastric cancer cells to TRAIL-induced cytotoxicity

The present study examined the role of TRAIL and DIM treatment, alone or in combination, on the proliferation of human gastric cancer cell lines BGC-823 and SGC-7901. The treatment of gastric cancer cells with 10 µmol/l DIM for 24 h induced marginal cytotoxicity (<20%). Similarly, limited cytotoxicity (20%) was observed following treatment with TRAIL at concentrations of 25–50 ng/ml. However, compared to treatment with TRAIL or DIM alone, significant cytotoxic effects were induced following co-treatment of the two gastric cancer cell lines with TRAIL (25 ng/ml) and DIM (10 µmol/l), compared with control (P=0.0001 in BGC-823, P=0.0001 in SGC-7901), TRAIL (P=0.0002 in BGC-823, P=0.0006 in SGC-7901) or DIM alone (P=0.0002 in BGC-823, P=0.0006 in SGC-7901 (Fig. 1).

Figure 1.

Effect of treatment with DIM or TRAIL alone or in combination, on the cytotoxicity of (A) BGC-823 and (B) SGC-7901 cells, as determined by a colorimetric water-soluble tetrazolium salt assay. DIM significantly sensitizes TRAIL-induced cytotoxicity of gastric cancer cells. Error bars indicate the standard deviation from the mean. DIM, 3,3′-diindolylmethane; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

DIM enhances TRAIL-induced apoptosis in gastric cancer cells

To investigate whether apoptosis is correlated with the inhibition of cell proliferation following DIM and TRAIL co-treatment, flow cytometric analysis was used to detect the increase in hypodiploid cell populations. The mean (n=3) proportions of late apoptotic BGC-823 cells were 15.1, 16.9, 19.4 and 39.7% for DIM (10 µmol/l), TRAIL (25 ng/ml), TRAIL (50 ng/ml), and TRAIL (25 ng/ml) plus DIM (10 µmol/l), respectively (Fig. 2A). Similarly, in SGC-7901 cells, the mean (n=3) proportions were 10.9, 13.9, 16.1 and 37.3% for DIM (10 µmol/l), TRAIL (25 ng/ml), TRAIL (50 ng/ml), and TRAIL (25 ng/ml) plus DIM (10 µmol/l) (Fig. 2B). These results indicate that DIM sensitizes gastric cancer cells to TRAIL-induced apoptosis.

Figure 2.

Effects of treatment with DIM or TRAIL alone or in combination, on the apoptosis of (A) BGC-823 and (B) SGC-7901 cells as determined by Annexin V-fluorescein isothiocyanate and PI staining. DIM significantly enhanced TRAIL-induced apoptosis of gastric cancer cells Error bars indicate the standard deviation from the mean. DMSO, dimethyl sulfoxide; DIM, 3,3′-diindolylmethane; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; PI, propidium iodide.

DIM plus TRAIL treatment induces the expression of DR5, CHOP and GRP78 proteins in gastric cancer cells

BGC-823 cells were treated with DIM for 24 h and subsequently analyzed by western blot to investigate the expression levels of various TRAIL receptor-associated proteins. The group of cells treated with TRAIL plus DIM were demonstrated to significantly induce the protein expression levels of DR5 (P<0.001) but exhibited no effect on DR4 expression. This data indicates that DR5 may be involved in DIM enhancement of the apoptotic effects of TRAIL in BGC-823 cells. Significant upregulation of DR5 by DIM plus TRAIL was also identified in SGC-7901 cells (P<0.05). Furthermore, DIM and TRAIL co-treatment was observed to induce a significant increase in the protein expression levels of CHOP and GRP78 (P>0.05; Fig. 3), two proteins that accumulate during endoplasmic reticulum (ER) stress (12).

Figure 3.

Effect of various DIM/TRAIL treatment strategies on the expression levels of DR5, DR4, CHOP and GRP78 in (A) BGC-823 and (B) SGC-7901 cells using western blot analysis. DIM plus TRAIL treatment significantly increased the protein expression levels of DR5, CHOP and GRP78 in gastric cancer cells. Error bars indicate the standard deviation from the mean. DIM, 3,3′-diindolylmethane; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; DR4/5, death receptor 4/5; CHOP, CCAAT/enhancer binding protein homologous protein; GRP78, glucose-regulated protein 78.

Discussion

In the present study, the potential anticancer effect of DIM, a bioactive product derived from cruciferous vegetables, in regulating TRAIL signaling was explored in two gastric cancer cell lines. DIM was demonstrated to potentiate TRAIL-induced apoptosis in the gastric cancer cell lines BGC-823 and SGC-7901, as well as inducing increased DR5, CHOP and GRP78 protein expression levels.

Cytotoxic and apoptotic effects were observed when gastric cancer cells were treated with DIM or TRAIL alone; these results are consistent with a number of previous studies on various types of cancer, including gastric cancer (13–15). However, to the best of our knowledge, the present study is the first to demonstrate that DIM sensitizes TRAIL-induced cytotoxicity and apoptosis in gastric cancer cells. As the widespread application of TRAIL has been limited due to increasing drug resistance and cost (3,4), the results of the current study indicate that the use of low-cost DIM may enhance the clinical application of TRAIL-based therapy for various types of cancer in the future.

El-Deiry (9) previously reported that effective TRAIL-based combination therapy may be achieved by the upregulation of DR4 and DR5. Furthermore, DIM appears to induce apoptosis in pancreatic cancer cells via ER stress-dependent upregulation of DR5 (16). Based on this data, we hypothesized that DIM potentiates TRAIL-induced apoptosis of gastric cancer cells by upregulating DR5 expression. In the current study, DIM and TRAIL co-treatment appeared to induce DR5 expression, confirming this hypothesis.

CHOP has been reported to directly regulate DR5 expression in human carcinoma cells (10,17). For example, specific agents, such as dimethyl-celecoxib and 5,7-dimethoxyflavone, have been shown to induce the expression of DR5 via CHOP-dependent DR5 gene transactivation (18,19). Furthermore, previous studies have identified a close association between DR5 expression and ER stress (10,17). In the ER lumen, ER stress is activated when unfolded proteins accumulate (20). Through this response, specific apoptotic pathways may be activated to clear severely damaged cells in which the defects of protein folding cannot be resolved (12,21). Although the molecular mechanisms by which ER stress inducers regulate DR5 expression may vary between cell types, CHOP, an ER stress-inducible transcription factor, provides a common association between ER stress and DR5 expression. In the present study, treatment of gastric cancer cells with DIM plus TRAIL was demonstrated to induce the expression of CHOP and GRP78, two proteins that also accumulate during ER stress (12). The identification of CHOP induction by DIM indicates that DIM may trigger ER stress and increase the expression levels of GRP78, although this mechanism has yet to be fully clarified.

In conclusion, to the best of knowledge, the present study demonstrates for the first time that DIM sensitizes TRAIL-induced cytotoxicity and apoptosis in gastric cancer cells, accompanied by the upregulation of DR5, CHOP and GRP78 protein expression levels. We propose that this process of sensitization may involve ER stress mechanisms. The results of the current study highlight the possibility of producing less costly anticancer agents in the future, and the use of low-cost DIM may enhance the clinical application of TRAIL-based therapy for various types of cancer. Thus, the results of this study indicate that future studies, which investigate the anticancer effects of other active components derived from the diet or Traditional Chinese medicine may be of value.

Acknowledgements

The present study was supported by the Research Foundation for Advanced Talents of Jiangsu University (grant nos. 14JDG044, 1291270021) and the Natural Science Foundation of Jiangsu Province (grant nos. BK20130502 and BK20140576), the open project of Key Lab of Modern Toxicology (grant no. NJMU), the Ministry of Education (grant no. NMUMT201410) and Jiangsu Planned Projects for Postdoctoral Research Funds (grant no. 1402169C).

References

1 

Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI

2 

Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI

3 

Belkhiri A, Zhu S, Chen Z, et al: Resistance to TRAIL is mediated by DARPP-32 in gastric cancer. Clin Cancer Res. 18:3889–3900. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Lane D, Côté M, Grondin R, et al: Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol Cancer Ther. 5:509–521. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Scott EN, Gescher AJ, Steward WP and Brown K: Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila). 2:525–530. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Fujioka N, Ainslie-Waldman CE, Upadhyaya P, et al: Urinary 3,3′-diindolylmethane: a biomarker of glucobrassicin exposure and indole-3-carbinol uptake in humans. Cancer Epidemiol Biomarkers Prev. 23:282–287. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Schröder M and Kaufman RJ: The mammalian unfolded protein response. Annu Rev Biochem. 74:739–789. 2005. View Article : Google Scholar : PubMed/NCBI

8 

Rutkowski DT and Kaufman RJ: A trip to the ER: coping with stress. Trends Cell Biol. 14:20–28. 2004. View Article : Google Scholar : PubMed/NCBI

9 

El-Deiry WS: Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 8:1066–1075. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Yamaguchi H and Wang HG: CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 279:45495–45502. 2004. View Article : Google Scholar : PubMed/NCBI

11 

Wang S, Wu X, Chen Y, et al: Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res. 18:2987–2996. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Szegezdi E, Logue SE, Gorman AM and Samali A: Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7:880–885. 2006. View Article : Google Scholar : PubMed/NCBI

13 

Lee SH, Min KW, Zhang X and Baek SJ: 3,3′-diindolylmethane induces activating transcription factor 3 (ATF3) via ATF4 in human colorectal cancer cells. J Nutr Biochem. 24:664–671. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Yin XF, Chen J, Mao W, et al: A selective aryl hydrocarbon receptor modulator 3,3′-diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res. 31:462012. View Article : Google Scholar : PubMed/NCBI

15 

Jalving M, Heijink DM, Koornstra JJ, et al: Regulation of TRAIL receptor expression by β-catenin in colorectal tumours. Carcinogenesis. 35:1092–1099. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Abdelrahim M, Newman K, Vanderlaag K, et al: 3,3′-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis. 27:717–728. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Yoshida T, Shiraishi T, Nakata S, et al: Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 65:5662–5667. 2005. View Article : Google Scholar : PubMed/NCBI

18 

Chen S, Liu X, Yue P, et al: CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells. Mol Pharmacol. 72:1269–1279. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Yang JF, Cao JG, Tian L and Liu F: 5,7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells. Cancer Chemother Pharmacol. 69:195–206. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Görlach A, Klappa P and Kietzmann T: The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal. 8:1391–1418. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Malhotra JD and Kaufman RJ: The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol. 18:716–731. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Ye Y, Miao S, Wang Y, Zhou J and Lu R: 3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells . Oncol Lett 9: 2393-2397, 2015.
APA
Ye, Y., Miao, S., Wang, Y., Zhou, J., & Lu, R. (2015). 3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells . Oncology Letters, 9, 2393-2397. https://doi.org/10.3892/ol.2015.3008
MLA
Ye, Y., Miao, S., Wang, Y., Zhou, J., Lu, R."3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells ". Oncology Letters 9.5 (2015): 2393-2397.
Chicago
Ye, Y., Miao, S., Wang, Y., Zhou, J., Lu, R."3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells ". Oncology Letters 9, no. 5 (2015): 2393-2397. https://doi.org/10.3892/ol.2015.3008
Copy and paste a formatted citation
x
Spandidos Publications style
Ye Y, Miao S, Wang Y, Zhou J and Lu R: 3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells . Oncol Lett 9: 2393-2397, 2015.
APA
Ye, Y., Miao, S., Wang, Y., Zhou, J., & Lu, R. (2015). 3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells . Oncology Letters, 9, 2393-2397. https://doi.org/10.3892/ol.2015.3008
MLA
Ye, Y., Miao, S., Wang, Y., Zhou, J., Lu, R."3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells ". Oncology Letters 9.5 (2015): 2393-2397.
Chicago
Ye, Y., Miao, S., Wang, Y., Zhou, J., Lu, R."3,3'‑diindolylmethane potentiates tumor necrosis factor‑related apoptosis‑inducing ligand-induced apoptosis of gastric cancer cells ". Oncology Letters 9, no. 5 (2015): 2393-2397. https://doi.org/10.3892/ol.2015.3008
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team